Numab

Wadenswil, Switzerland

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.

$54.9M raised

Jan 2025

Series C

Top Investors

BlackRockMitsubishi UFJ CapitalCormorant Asset ManagementRTW InvestmentsNovo Holdings

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Numab raised?

Numab has raised $54.9M in total funding. The most recent round was Series C. The last funding was announced in January 2025.

Who are Numab's investors?

Numab's investors include BlackRock, Mitsubishi UFJ Capital, Cormorant Asset Management, RTW Investments, Novo Holdings.

Where is Numab headquartered?

Numab is headquartered in Wadenswil, Switzerland.

What does Numab do?

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.

What stage is Numab at?

Numab is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 9, 2025.

MLA

"Numab — Funding & Investors." VCBacked, January 9, 2025, https://www.vcbacked.co/company/numab. Accessed June 3, 2026.

APA

VCBacked. (2025). Numab — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/numab

Wikipedia (cite web)

{{cite web |title=Numab — Funding & Investors |url=https://www.vcbacked.co/company/numab |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 9, 2025.